Tscan Therapeutics Inc

NASDAQ:TCRX  
6.43
-0.19 (-2.87%)
Earnings Announcements

TScan Therapeutics Reports Third Quarter 2021 Financial Results

Published: 11/10/2021 12:29 GMT
Tscan Therapeutics Inc (TCRX) - Tscan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress.
Q3 Loss per Share $0.80.
Revenue is expected to be $3.87 Million
Adjusted EPS is expected to be -$0.66

Next Quarter Revenue Guidance is expected to be $4.01 Million
Next Quarter EPS Guidance is expected to be -$2.32

More details on our Analysts Page.